platelet count

血小板数 -> 血小板

WordNet

1. name or recite the numbers in ascending order; "The toddler could count to 100"
2. the total number counted; "a blood count"
3. the act of counting; reciting numbers in ascending order; "the counting continued for several hours" (同)counting, numeration, enumeration, reckoning, tally
4. a nobleman (in various countries) having rank equal to a British earl
5. have faith or confidence in; "you can count on me to help you any time"; "Look to your friends for support"; "You can bet on that!"; "Depend on your family in times of crisis" (同)bet, depend, look, calculate, reckon
6. have weight; have import, carry weight; "It does not matter much" (同)matter, weigh
7. put into a group; "The academy counts several Nobel Prize winners among its members" (同)number
8. determine the number or amount of; "Can you count the books on your shelf?"; "Count your change" (同)number, enumerate, numerate
9. have a certain value or carry a certain weight; "each answer counts as three points"
10. include as if by counting; "I can count my colleagues in the opposition"
11. tiny bits of protoplasm found in vertebrate blood; essential for blood clotting (同)blood_platelet, thrombocyte

PrepTutorEJDIC

1. (一つ一つ順に)〈数〉'を'『数える』,〈物〉'を'数え上げる《+『up』+『名,』+『名』+『up』》 / …'を'『勘定に入れる』,含める(include) / …'を'『思う』,みなす(consider) / 数を数える,計算する《+『up』》 / 数にはいる,数に含まれる / 価値がある,重大である / 〈C〉〈U〉『数えること』,『計算』 / 〈U〉総数,総計 / 〈U〉(起訴状の)訴因 / 《the~》(ボクシングで)カウント(選手がノックダウンされたときレフリーが1から10まで数えること) / 〈C〉(野救で打者の)ボールカウント / 〈U〉《話》考慮,注目(account)
2. (英国以外の)伯爵

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2018/10/15 01:34:50」(JST)

wiki en

[Wiki en表示]

Platelets
Image from a light microscope (500 ×) from a Giemsa-stained peripheral blood smear showing platelets (blue dots) surrounded by red blood cells (pink circular structures)
Details
Precursor	Megakaryocytes
Function	Formation of blood clots; prevention of bleeding
Identifiers
Latin	Thrombocytes
Anatomical terms of microanatomy

Platelets, also called thrombocytes (from Greek θρόμβος, "clot" and κύτος, "cell"), are a component of blood whose function (along with the coagulation factors) is to react to bleeding from blood vessel injury by clumping, thereby initiating a blood clot. Platelets have no cell nucleus: they are fragments of cytoplasm that are derived from the megakaryocytes of the bone marrow, and then enter the circulation. Circulating unactivated platelets are biconvex discoid (lens-shaped) structures, 2–3 µm in greatest diameter. Platelets are found only in mammals, whereas in other animals (e.g. birds, amphibians) thrombocytes circulate as intact mononuclear cells.

The ligands, denoted by letter L, signal for platelets (P) to migrate towards the wound (Site A). As more platelets gather around the opening, they produce more ligands to amplify the response. The platelets congregate around the wound in order to create a cap to stop blood flow out of the tissue.

On a stained blood smear, platelets appear as dark purple spots, about 20% the diameter of red blood cells. The smear is used to examine platelets for size, shape, qualitative number, and clumping. The ratio of platelets to red blood cells in a healthy adult ranges from 1:10 to 1:20.

The main function of platelets is to contribute to hemostasis: the process of stopping bleeding at the site of interrupted endothelium. They gather at the site and unless the interruption is physically too large, they plug the hole. First, platelets attach to substances outside the interrupted endothelium: adhesion. Second, they change shape, turn on receptors and secrete chemical messengers: activation. Third, they connect to each other through receptor bridges: aggregation. Formation of this platelet plug (primary hemostasis) is associated with activation of the coagulation cascade with resultant fibrin deposition and linking (secondary hemostasis). These processes may overlap: the spectrum is from a predominantly platelet plug, or "white " to a predominantly fibrin , or "red " or the more typical mixture. Some would add the subsequent retraction and platelet inhibition as fourth and fifth steps to the completion of the process and still others a sixth step wound repair.

Recently, signs of platelets' function as cells of both innate and adaptive immune system are coming into focus, with platelets immune role being attributed both to hemostatic function and other distinct secretory functions.

Low platelet concentration is thrombocytopenia and is due to either decreased production or increased destruction. Elevated platelet concentration is thrombocytosis and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloproliferative neoplasms or certain other myeloid neoplasms. A disorder of platelet function is a thrombocytopathy.

Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis: the formation of a within an intact vessel. This type of thrombosis arises by mechanisms different than those of a normal : namely, extending the fibrin of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia, or may completely obstruct it, causing downstream tissue death.

Measurement

Platelet concentration is measured either manually using a hemocytometer, or by placing blood in an automated platelet analyzer using electrical impedance, such as a Coulter counter. The normal range (99% of population analyzed) for platelets in healthy Caucasians is 150,000 to 450,000 per cubic millimeter (a mm³ equals a microliter). or 150–450 × 10⁹ per liter. The normal range has been confirmed to be the same in the elderly and Spanish populations.

Structure

Structurally the platelet can be divided into four zones, from peripheral to innermost:

• Peripheral zone – is rich in glycoproteins required for platelet adhesion, activation, and aggregation. For example, GPIb/IX/X; GPVI; GPIIb/IIIa.
• Sol-gel zone – is rich in microtubules and microfilaments, allowing the platelets to maintain their discoid shape.
• Organelle zone – is rich in platelet granules. Alpha granules contain ting mediators such as factor V, factor VIII, fibrinogen, fibronectin, platelet-derived growth factor, and chemotactic agents. Delta granules, or dense bodies, contain ADP, calcium, serotonin, which are platelet-activating mediators.
• Membranous zone – contains membranes derived from megakaryocytic smooth endoplasmic reticulum organized into a dense tubular system which is responsible for thromboxane A2 synthesis. This dense tubular system is connected to the surface platelet membrane to aid thromboxane A2 release.

Development

Platelets derive from totipotent marrow stem cells

• Megakaryocyte and platelet production is regulated by thrombopoietin, a hormone produced in the kidneys and liver.
• Each megakaryocyte produces between 1,000 and 3,000 platelets during its lifetime.
• An average of 10¹¹ platelets are produced daily in a healthy adult.
• Reserve platelets are stored in the spleen, and are released when needed by splenic contraction induced by the sympathetic nervous system.

Platelets extruded from megakaryocytes

• The average life span of circulating platelets is 8 to 9 days. Life span of individual platelets is controlled by the internal apoptotic regulating pathway, which has a Bcl-x_L timer.
• Old platelets are destroyed by phagocytosis in the spleen and liver.

Hemostasis

3D rendering of four inactivated and three activated platelets.

An overview summarizing platelet dynamics, the complex process of converting inactive platelets into a platelet plug, is essential^{EL 2}. Complicating any verbal description is the fact that at least 193 proteins and 301 interactions are involved in platelet dynamics. The separation of platelet dynamics into three stages is useful in this regard, but it is artificial: in fact, each stage is initiated in rapid succession, and each continues until the trigger for that stage is no longer present, so there is overlap.

Adhesion

Thrombus formation on an intact endothelium is prevented by nitric oxide, prostacyclin, and CD39.

Endothelial cells are attached to the subendothelial collagen by von Willebrand factor (VWF) which these cells produce. VWF is also stored in the Weibel-Palade bodies of the endothelial cells and secreted constitutively into the blood. Platelets store vWF in their alpha granules.

When the endothelial layer is disrupted, collagen and VWF anchor platelets to the subendothelium. Platelet GP1b-IX-V receptor binds with VWF; and GPVI receptor and integrin alpha2beta1 bind with collagen.

Activation

Scanning electron micrograph of blood cells. From left to right: human erythrocyte, activated platelet, leukocyte.

Inhibition

The intact endothelial lining inhibits platelet activation by producing nitric oxide, endothelial-ADPase, and PGI₂ (Prostacyclin). Endothelial-ADPase degrades the platelet activator ADP.

Resting platelets maintain active calcium efflux via a cyclic AMP activated calcium pump. Intracellular calcium concentration determines platelet activation status, as it is the second messenger that drives platelet conformational change and degranulation (see below). Endothelial prostacyclin binds to prostanoid receptors on the surface of resting platelets. This event stimulates the coupled Gs protein to increase adenylate cyclase activity and increases the production of cAMP, further promoting the efflux of calcium and reducing intracellular calcium availability for platelet activation.

ADP on the other hand binds to purinergic receptors on platelet surface. Since the thrombocytic purinergic receptor P2Y12 is coupled to Gi proteins, ADP reduces platelet adenylate cyclase activity and cAMP production, leading to accumulation of calcium inside the platelet by inactivating the cAMP calcium efflux pump. The other ADP-receptor P2Y1 couples to Gq that activates phospholipase C-beta 2 PLCB2, resulting in inositol 1,4,5-trisphosphate (IP3)generation and intracellular release of more calcium. This together induces platelet activation. Endothelial ADPase degrades ADP and prevents this from happening. Clopidogrel and related antiplatelet medications also work as purinergic receptor P2Y12 antagonists.

Trigger (induction)

Platelet activation begins seconds after adhesion occurs. It is triggered when collagen from the subendothelium binds with its receptors on the platelet. GPVI is associated with the Fc receptor gamma chain and leads via the activation of a tyrosine kinase cascade finally to the activation of PLC-gamma2 PLCG2 and more calcium release.

Tissue factor also binds to factor VII in the blood, which initiates the extrinsic coagulation cascade to increase thrombin production. Thrombin is a potent platelet activator, acting through Gq and G12. These are G protein coupled receptors and they turn on calcium mediated signaling pathways within the platelet, overcoming the baseline calcium efflux. Families of three G proteins (Gq, Gi, G12) operate together for full activation. Thrombin also promotes secondary fibrin-reinforcement of the platelet plug. Platelet activation in turn degranulates and releases factor V and fibrinogen, potentiating the coagulation cascade. So in reality the process of platelet plugging and coagulation are occurring simultaneously rather than sequentially, with each inducing the other to form the final .

Components (consequences)

GPIIb/IIIa activation

Collagen-mediated GPVI signalling increases the platelet production of thromboxane A2 (TXA2) and decreases the production of prostacyclin. This occurs by altering the metabolic flux of platelet's eicosanoid synthesis pathway, which involves enzymes phospholipase A2, cyclo-oxygenase 1, and thromboxane-A synthase. Platelets secrete thromboxane A2, which acts on the platelet's own thromboxane receptors on the platelet surface (hence the so-called "out-in" mechanism), and those of other platelets. These receptors trigger intraplatelet signaling, which converts GPIIb/IIIa receptors to their active form to initiate aggregation.

Granule secretion

Diagram of the structure of a platelet showing the granules

Platelets contain dense granules, lambda granules and alpha granules. Activated platelets secrete the contents of these granules through their canalicular systems to the exterior. Simplistically, bound and activated platelets degranulate to release platelet chemotactic agents to attract more platelets to the site of endothelial injury. Granule characteristics:

• α granules (alpha granules) – containing P-selectin, platelet factor 4, transforming growth factor-β1, platelet-derived growth factor, fibronectin, B-thromboglobulin, vWF, fibrinogen, and coagulation factors V and XIII.
• δ granules (delta or dense granules) – containing ADP or ATP, calcium, and serotonin.
• γ granules (gamma granules) – similar to lysosomes and contain several hydrolytic enzymes.
• λ granules (lambda granules) – contents involved in resorption during later stages of vessel repair.

Morphology change

Mitochondria hyperpolarization is a key event in initiating changes in morphology. Intraplatelet calcium concentration increases, stimulating the interplay between microtubule/actin filament complex. The continuous changes in shape from the unactivated to the fully activated platelet is best seen on scanning electron microscopy. Three steps along this path are named early dendritic, early spread and spread. The surface of the unactivated platelet looks very similar to the surface of the brain, with a wrinkled appearance from numerous shallow folds to increase the surface area; early dendritic, an octopus with multiple arms and legs; early spread, an uncooked frying egg in a pan, the "yolk" being the central body; and the spread, a cooked fried egg with a denser central body. These changes are all brought about by the interaction of the microtubule/actin complex with the platelet cell membrane and open canalicular system (OCS), which is an extension and invagination of that membrane. This complex runs just beneath these membranes, and is the chemical motor which literally pulls the invaginated OCS out of the interior of the platelet like turning pants pockets inside out, creating the dendrites. and then spreads each dendrite until the entire OCS becomes indistinguishable from the initial platelet membrane as it forms the "fried egg". This dramatic increase in surface area comes about with neither stretching nor adding phospholipids to the platelet membrane.

Platelet-coagulation factor interactions: coagulation facilitation

Platelet activation causes its membrane surface to become negatively charged. One of the signaling pathways turns on scramblase, which moves negatively charged phospholipids from the inner to the outer platelet membrane surface. These phospholipids then bind the tenase and prothrombinase complexes, two of the sites of interplay between platelets and the coagulation cascade. Calcium ions are essential for the binding of these coagulation factors.

In addition to interacting with vWF and fibrin, platelets interact with thrombin, Factors X, Va, VIIa, XI, IX, and prothrombin to complete formation via the coagulation cascade.

Six studies suggested platelets express tissue factor: the definitive study shows they do not. The platelets from rats were conclusively shown to express tissue factor protein and also it was proved that the rat platelets carry both the tissue factor pre-mRNA and mature mRNA.

Aggregation

Platelet clumps in a blood smear

Aggregation begins minutes after activation, and occurs as a result of turning on the GPIIb/IIIa receptor, allowing these receptors to bind with vWF or fibrinogen. There are around 60 000 of these receptors per platelet. When any one or more of at least nine different platelet surface receptors are turned on during activation, intraplatelet signaling pathways cause existing GpIIb/IIIa receptors to change shape – curled to straight – and thus become capable of binding.

Since fibrinogen is a rod-like protein with nodules on either end capable of binding GPIIb/IIIa, activated platelets with exposed GPIIb/IIIa can bind fibrinogen to aggregate. GPIIb/IIIa may also further anchor the platelets to subendothelial vWF for additional structural stabilisation.

Classically it was thought that this was the only mechanism involved in aggregation, but three new mechanisms have been identified which can initiate aggregation, depending on the velocity of blood flow (i.e. shear range).

Wound repair

Main article: Wound repair

The blood is only a temporary solution to stop bleeding; tissue repair is needed. Small interruptions in the endothelium are handled by physiological mechanisms; large interruptions by the trauma surgeon. The fibrin is slowly dissolved by the fibrinolytic enzyme, plasmin, and the platelets are cleared by phagocytosis.

Immune function

Platelets have central role in innate immunity, initiating and participating in multiple inflammatory processes, directly binding pathogens and even destroying them. This support clinical data which show that significant amount of a patients with serious bacterial or viral infections suffer from thrombocytopenia, thus reducing their contribution to inflammation. Also platelet-leukocyte aggregates (PLAs) found in circulation are typical in sepsis or inflammatory bowel disease, showing the connection between thrombocytes and immune cells sensu stricto.

Immunothrombosis

As hemostasis is basic function of thrombocytes in mammals, it has also its uses in possible infection confinement. In case of injury, platelets, together with the coagulation cascade, form the first line of defense forming blood clot. Thus, hemostasis and host defense were intertwined in evolution. For example, in Atlantic horseshoe crab (living fossil whose origin is estimated to be over 400 million years old), its only blood cell type, the amebocytes, facilitate both the hemostatic function as well as encapsulation and phagocytosis of the pathogens by the means of exocytosis of their intracellular granules containing bactericidal defense molecules. Blood clotting supports the immune function by trapping the pathogenic bacteria within.

Although thrombosis, blood coagulation in intact blood vessels, is usually viewed as a pathological immune response, leading to obturation of lumen of blood vessel and subsequent hypoxic tissue damage, in some cases, directed thrombosis, called immunothrombosis, can localy control the spread of the infection. The thrombosis is directed in concordance of platelets, neutrophils and monocytes. The process is initiated either by immune cells sensu stricto by activating their pattern recognition receptors (PRRs), or by platelet-bacterial binding. Platelets can bind to bacteria either directly through thrombocytic PRRs and bacterial surface proteins, or via plasma proteins that bind both to platelets and bacteria. Monocytes respond to bacterial pathogen-associated molecular patterns (PAMPs), or damage-associated molecular patterns (DAMPs) by activating the extrinsic pathway of coagulation. Neutrophils facilitate the blood coagulation by NETosis. In turn, the platelets facilitate neutrophils' NETosis. NETs bind tissue factor, binding the coagulation centres to the location of infection. They also activate the intrinsic coagulation pathway by providing its negatively charged surface to the factor XII. Other neutrophil secretions, such as proteolytic enzymes, which cleave coagulation inhibitors, also bolster the process.

In case of inbalance throughout the regulation of immunothrombosis, this process can quickly become aberrant. Regulatory defects in immunothrombosis are suspected to be major factor in causing pathological thrombosis in many forms, such as disseminated intravascular coagulation (DIC) or deep vein thrombosis. DIC in sepsis is a prime example of both dysregulated coagulation process as well as undue systemic inflammatory response resulting in multitude of microthrombi of similar composition to that in physiological immunothrombosis - fibrin, platelets, neutrophils and NETs.

Inflammation

Platelets are rapidly deployed to sites of injury or infection, and potentially modulate inflammatory processes by interacting with leukocytes and by secreting cytokines, chemokines and other inflammatory mediators. Platelets also secrete platelet-derived growth factor (PDGF).

Platelets modulate neutrophils by forming platelet-leukocyte aggregates (PLAs). These formation induce upregulated production of αmβ2 (Mac-1) integrin in neutrophils. Interaction with PLAs also induce degranulation and increased phagocytosis in neutrophils. Platelets are also the largest source of soluble CD40L which induces production of reactive oxygen species (ROS) and upregulate expression of adhesion molecules, such as E-selectin, ICAM-1 and VCAM-1, in neutrophils, activates macrophages and activates cytotoxic response in T and B lymphocytes.

Recently, the dogma that mammalian platelets lacking nucleus are unable of autonomous locomotion was broken. In fact, the platelets are active scavengers, scaling walls of blood vessels and reorganising the thrombus. They are able to recognize and adhere to many surfaces, including bacteria. They are even able to fully envelop them in their open canalicular system (OCP), leading to proposed name of the process being "covercytosis", rather than phagocytosis, as OCS is merely an invagination of outer plasma membrane. These platelet-bacteria bundles are then used as an interation platform for neutrophilsm which destroy the bacteria using the NETosis and phagocytosis.

Platelets also participate in chronic inflammatory diseases, such as synovitis or rheumatoid arthritis. Platelets are activated by collagen receptor glycoprotein IV (GPVI). Proinflammatory platelet microvesicles trigger constant cytokine secretion from neighboring fibroblast-like synoviocytes, most prominently Il-6 and Il-8. Inflammatory damage to surrounding extracellular matrix continually reveals more collagen, maintaining the microvesicle production.

Adaptive immunity

Activated platelets are able to participate in adaptive immunity, interacting with antibodies. They are able to specifically bind IgG through FcγRIIA, receptor for constant fragment (Fc) of IgG. When activated and bound to IgG opsonised bacteria, the platelets subsequently release reactive oxygen species (ROS), antimicrobial peptides, defensins, kinocidins and proteases, killing the bacteria directly. Platelets also secrete proinflammatory and procoagulant mediators such as inorganic polyphosphates or platelet factor 4 (PF4), connecting innate and adaptive immune responses.

Clinical significance

Signs and symptoms

Spontaneous and excessive bleeding can occur because of platelet disorders. This bleeding can be caused by deficient numbers of platelets, dysfunctional platelets, or very excessive numbers of platelets: over 1.0 million/microliter. (The excessive numbers create a relative von Willebrand factor deficiency due to sequestration.)

One can get a clue as to whether bleeding is due to a platelet disorder or a coagulation factor disorder by the characteristics and location of the bleeding. All of the following suggest platelet bleeding, not coagulation bleeding: the bleeding from a skin cut such as a razor nick is prompt and excessive, but can be controlled by pressure; spontaneous bleeding into the skin which causes a purplish stain named by its size: petechiae, purpura, ecchymoses; bleeding into mucous membranes causing bleeding gums, nose bleed, and gastrointestinal bleeding; menorrhagia; and intraretinal and intracranial bleeding.

Excessive numbers of platelets, and/or normal platelets responding to abnormal vessel walls, can result in venous thrombosis and arterial thrombosis. The symptoms depend on the site of thrombosis.

Tests of platelet function

Bleeding time

Developed by Duke in 1910 and bearing his name, it measured the time for bleeding to stop from a standardized wound in the ear lobe which is blotted each 30 seconds. Normal was less than 3 minutes. More modern techniques are now used. A normal bleeding time reflects sufficient platelet numbers and function plus normal microvasculature.

Multiplate multiple electrode aggregometry

In the Multiplate analyzer, anticoagulated whole blood is mixed with saline and a platelet agonist in a single use cuvette with two pairs of electrodes. The increase in impedance between the electrodes as platelets aggregate onto them, is measured and visualized as a curve.

PFA-100

The PFA-100 (Platelet Function Assay-100) is a system for analysing platelet function in which citrated whole blood is aspirated through a disposable cartridge containing an aperture within a membrane coated with either collagen and epinephrine or collagen and ADP. These agonists induce platelet adhesion, activation and aggregation leading to rapid occlusion of the aperture and cessation of blood flow termed the closure time (CT). An elevated CT with EPI and collagen can indicate intrinsic defects such as von Willebrand disease, uremia, or circulating platelet inhibitors. The follow up test involving collagen and ADP is used to indicate if the abnormal CT with collagen and EPI was caused by the effects of acetyl sulfosalicylic acid (aspirin) or medications containing inhibitors.

Platelet disorders

Adapted from:

The three broad categories of platelet disorders are "not enough"; "dysfunctional"; and "too many".

Thrombocytopenia

• Immune thrombocytopenias (ITP) – formerly known as immune thrombocytopenic purpura and idiopathic thrombocytopenic purpura
• Splenomegaly
  • Gaucher's disease
• Familial thrombocytopenia
• Chemotherapy
• Babesiosis
• Dengue
• Onyalai
• Thrombotic thrombocytopenic purpura
• HELLP syndrome
• Hemolytic-uremic syndrome
• Drug-induced thrombocytopenic purpura (five known drugs – most problematic is heparin-induced thrombocytopenia (HIT)
• Pregnancy associated
• Neonatal alloimmune associated
• Aplastic anemia
• Transfusion associated
• Pseudothrombocytopenia
• idiopathic thrombocytopenic purpura
• Gilbert's Syndrome

Altered platelet function

• Congenital
  • Disorders of adhesion
    • Bernard-Soulier syndrome
  • Disorders of activation
    • Disorders of granule amount or release
    • Hermansky-Pudlak Syndrome
    • Gray platelet syndrome
    • ADP Receptor defect
    • Decreased cyclooxygenase activity
    • Storage pool defects, acquired or congenital
  • Disorders of aggregation
    • Glanzmann's thrombasthenia
    • Wiskott–Aldrich syndrome
• Acquired
  • Disorders of adhesion
    • Paroxysmal nocturnal hemoglobinuria
    • Asthma
    • Samter's triad (aspirin exacerbated respiratory disease/AERD)
    • Cancer
    • Malaria
    • Decreased cyclooxygenase activity

Thrombocytosis and thrombocythemia

• Reactive
  • Chronic infection
  • Chronic inflammation
  • Malignancy
  • Hyposplenism (post-splenectomy)
  • Iron deficiency
  • Acute blood loss
• Myeloproliferative neoplasms – platelets are both elevated and activated
  • Essential thrombocytosis
  • Polycythemia vera
• Associated with other myeloid neoplasms
• Congenital

Drugs affecting platelets

Anti-inflammatory drugs

Some drugs used to treat inflammation have the unwanted side effect of suppressing normal platelet function. These are the non-steroidal anti-inflammatory drugs (NSAIDS). Aspirin irreversibly disrupts platelet function by inhibiting cyclooxygenase-1 (COX1), and hence normal hemostasis. The resulting platelets are unable to produce new cyclooxygenase because they have no DNA. Normal platelet function will not return until the use of aspirin has ceased and enough of the affected platelets have been replaced by new ones, which can take over a week. Ibuprofen, another NSAID, does not have such a long duration effect, with platelet function usually returning within 24 hours, and taking ibuprofen before aspirin prevents the irreversible effects of aspirin.

Drugs that suppress platelet function

These drugs are used to prevent thrombus formation.

Oral agents

• aspirin
• clopidogrel
• cilostazol
• ticlopidine
• ticagrelor
• prasugrel

Drugs that stimulate platelet production

• thrombopoietin mimetics
• desmopressin
• factor VIIa

Intravenous agents

• abciximab,
• eptifibatide
• tirofiban
• Others oprelvekin, romiplostim, eltrombopag, argatroban

Therapy with platelets

Transfusion

Main article: Platelet transfusion

Indications

Platelet transfusion is most frequently used to correct unusually low platelet counts, either to prevent spontaneous bleeding (typically at counts below 10×10⁹/L) or in anticipation of medical procedures that will necessarily involve some bleeding. For example, in patients undergoing surgery, a level below 50×10⁹/L is associated with abnormal surgical bleeding, and regional anaesthetic procedures such as epidurals are avoided for levels below 80×10⁹/L. Platelets may also be transfused when the platelet count is normal but the platelets are dysfunctional, such as when an individual is taking aspirin or clopidogrel. Finally, platelets may be transfused as part of a massive transfusion protocol, in which the three major blood components (red blood cells, plasma, and platelets) are transfused to address severe hemorrhage. Platelet transfusion is contraindicated in thrombotic thrombocytopenic purpura (TTP), as it fuels the coagulopathy.

Collection

Platelet concentrate.

Platelets are either isolated from collected units of whole blood and pooled to make a therapeutic dose, or collected by platelet apheresis: blood is taken from the donor, passed through a device which removes the platelets, and the remainder is returned to the donor in a closed loop. The industry standard is for platelets to be tested for bacteria before transfusion to avoid septic reactions, which can be fatal. Recently the AABB Industry Standards for Blood Banks and Transfusion Services (5.1.5.1) has allowed for use of pathogen reduction technology as an alternative to bacterial screenings in platelets.

Pooled whole-blood platelets, sometimes called “random” platelets, are separated by one of two methods. In the US, a unit of whole blood is placed into a large centrifuge in what is referred to as a “soft spin.” At these settings, the platelets remain suspended in the plasma. The platelet-rich plasma (PRP) is removed from the red cells, then centrifuged at a faster setting to harvest the platelets from the plasma. In other regions of the world, the unit of whole blood is centrifuged using settings that cause the platelets to become suspended in the “buffy coat” layer, which includes the platelets and the white blood cells. The “buffy coat” is isolated in a sterile bag, suspended in a small amount of red blood cells and plasma, then centrifuged again to separate the platelets and plasma from the red and white blood cells. Regardless of the initial method of preparation, multiple donations may be combined into one container using a sterile connection device to manufacture a single product with the desired therapeutic dose.

Apheresis platelets are collected using a mechanical device that draws blood from the donor and centrifuges the collected blood to separate out the platelets and other components to be collected. The remaining blood is returned to the donor. The advantage to this method is that a single donation provides at least one therapeutic dose, as opposed to the multiple donations for whole-blood platelets. This means that a recipient is not exposed to as many different donors and has less risk of transfusion-transmitted disease and other complications. Sometimes a person such as a cancer patient who requires routine transfusions of platelets will receive repeated donations from a specific donor to further minimize the risk. Pathogen reduction of platelets using for example, riboflavin and UV light treatments can also be carried out to reduce the infectious load of pathogens contained in donated blood products, thereby reducing the risk of transmission of transfusion transmitted diseases. Another photochemical treatment process utilizing amotosalen and UVA light has been developed for the inactivation of viruses, bacteria, parasites, and leukocytes that can contaminate blood components intended for transfusion. In addition, apheresis platelets tend to contain fewer contaminating red blood cells because the collection method is more efficient than “soft spin” centrifugation at isolating the desired blood component.

Storage

Platelets collected by either method have a very short shelf life, typically five days. This results in frequent problems with short supply, as testing the donations often requires up to a full day. Since there are no effective preservative solutions for platelets, they lose potency quickly and are best when fresh.

Platelets are stored under constant agitation at 20–24 °C (68–75.2 °F). Units can not be refrigerated as this causes platelets to change shape and lose function. Storage at room temperature provides an environment where any bacteria that are introduced to the blood component during the collection process may proliferate and subsequently cause bacteremia in the patient. Regulations are in place in the United States that require products to be tested for the presence of bacterial contamination before transfusion.

Delivery to recipients

Platelets do not need to belong to the same A-B-O blood group as the recipient or be cross-matched to ensure immune compatibility between donor and recipient unless they contain a significant amount of red blood cells (RBCs). The presence of RBCs imparts a reddish-orange color to the product, and is usually associated with whole-blood platelets. An effort is sometimes made to issue type specific platelets, but this is not critical as it is with RBCs.

Prior to issuing platelets to the recipient, they may be irradiated to prevent transfusion-associated graft versus host disease or they may be washed to remove the plasma if indicated.

The change in the recipient's platelet count after transfusion is termed the "increment" and is calculated by subtracting the pre-transfusion platelet count from the post-transfusion platelet count. Many factors affect the increment including the recipient's body size, the number of platelets transfused, and clinical features that may cause premature destruction of the transfused platelets. When recipients fail to demonstrate an adequate post-transfusion increment, this is termed platelet transfusion refractoriness.

Platelets, either apheresis-derived or random-donor, can be processed through a volume reduction process. In this process, the platelets are spun in a centrifuge and the excess plasma is removed, leaving 10 to 100 mL of platelet concentrate. Such volume-reduced platelets are normally transfused only to neonatal and pediatric patients, when a large volume of plasma could overload the child's small circulatory system. The lower volume of plasma also reduces the chances of an adverse transfusion reaction to plasma proteins. Volume reduced platelets have a shelf life of only four hours.

Wound therapy

Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the deposition of extracellular matrix; fibroblast growth factor, insulin-like growth factor 1, platelet-derived epidermal growth factor, and vascular endothelial growth factor. Local application of these factors in increased concentrations through Platelet-rich plasma (PRP) is used as an adjunct in wound healing.

Other animals

Instead of having platelets, non-mammalian vertebrates have nucleated thrombocytes, which resemble B lymphocytes in morphology. They aggregate in response to thrombin, but not to ADP, serotonin, nor adrenaline, as platelets do.

History

• George Gulliver in 1841 drew pictures of platelets using the twin lens (compound) microscope invented in 1830 by Joseph Jackson Lister. This microscope improved resolution sufficiently to make it possible to see platelets for the first time.
• William Addison in 1842 drew pictures of a platelet-fibrin clot.
• Lionel Beale in 1864 was the first to publish a drawing showing platelets.
• Max Schultze in 1865 described what he called "spherules", which he noted were much smaller than red blood cells, occasionally clumped, and were sometimes found in collections of fibrin material.
• Giulio Bizzozero in 1882 studied the blood of amphibians microscopically in vivo. He named Schultz's spherules (It.) piastrine: little plates.
• William Osler observed them and, in published lectures in 1886, called them a third corpuscle and a blood plaque and described them as a colorless protoplasmic disc.
• James Wright examined blood smears using the stain named for him, and used the term plates in his 1906 publication but changed to platelets in his 1910 publication which has become the universally accepted term.

The term thrombocyte (clot cell) came into use in the early 1900s and is sometimes used as a synonym for platelet; but not generally in the scientific literature, except as a root word for other terms related to platelets (e.g. thrombocytopenia meaning low platelets). Thrombocytes are cells found in the blood of non-mammalian vertebrates. They are the functional equivalents of platelets, but circulate as intact mononuclear cells, and are not simply cytoplasmic fragments of bone marrow megakaryocytes.

In some contexts, the word thrombus is used interchangeably with the word clot, regardless of its composition (white, red, or mixed). In other contexts it is used to contrast a normal from an abnormal clot: thrombus arises from physiologic hemostasis, thrombosis arises from a pathologic and excessive quantity of clot. In a third context it is used to contrast the result from the process: thrombus is the result, thrombosis is the process.

External links

• Video summarizing platelet dynamics ( Page will play audio when loaded)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 原因不明の血小板減少症を有する成人に対するアプローチ approach to the adult with unexplained thrombocytopenia
• 2. 血小板機能検査 platelet function testing
• 3. 原因不明の血小板減少症が生じた小児へのアプローチ approach to the child with unexplained thrombocytopenia
• 4. 術中に成人に行う成分輸血 intraoperative transfusion of blood products in adults
• 5. 血小板増加症患者に対するアプローチ approach to the patient with thrombocytosis

English Journal

• Important clinical and laboratory correlates of glomerular filtration rate in sickle cell anemia.

• Madu AJ1, Ubesie A, Ocheni S, Chinawa J, Madu KA, Ibegbulam OG, Nlemadim C, Eze A.
• Nigerian journal of clinical practice.Niger J Clin Pract.2015 Sep-Oct;18(5):633-7. doi: 10.4103/1119-3077.154220.
• BACKGROUND: Renal impairment is routinely assessed using the estimated glomerular filtration rate (eGFR) and it may be helpful to obtain certain clinical or laboratory markers, which show relationship with glomerular filtration rate (GFR) in sickle cell disease (SCD).AIM: To assess the relationship
• PMID 26096242

• Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation.

• Olin P1, Hausken J, Foss A, Karlsen TH, Melum E, Haugaa H.
• Scandinavian journal of gastroenterology.Scand J Gastroenterol.2015 Sep;50(9):1127-34. doi: 10.3109/00365521.2015.1027262. Epub 2015 Apr 11.
• OBJECTIVE: The molecular adsorbent recirculating system (MARS) is used to purify blood from albumin-bound toxins in patients with liver failure. However, the application of MARS has not demonstrated improved survival in randomized clinical trials and the clinical utility has not been finally establi
• PMID 25865318

• A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration.

• King LY1, Canasto-Chibuque C2, Johnson KB1, Yip S2, Chen X2, Kojima K2, Deshmukh M2, Venkatesh A2, Tan PS3, Sun X2, Villanueva A4, Sangiovanni A5, Nair V6, Mahajan M7, Kobayashi M8, Kumada H8, Iavarone M5, Colombo M5, Fiel MI9, Friedman SL2, Llovet JM10, Chung RT1, Hoshida Y2.
• Gut.Gut.2015 Aug;64(8):1296-302. doi: 10.1136/gutjnl-2014-307862. Epub 2014 Aug 20.
• OBJECTIVE: The number of patients with HCV-related cirrhosis is increasing, leading to a rising risk of complications and death. Prognostic stratification in patients with early-stage cirrhosis is still challenging. We aimed to develop and validate a clinically useful prognostic index based on genom
• PMID 25143343

Japanese Journal

• 〈Case Reports〉Hepatocellular carcinoma accompanied by hypersplenism: five cases of simultaneous hepatectomy and laparoscopic splenectomy

• Nakata Yasuyuki,Haji Seiji,Yamasaki Mitsuo,Ishikawa Hajime,Yasuda Takeo,Nakai Takuya,Takeyama Yoshifumi
• Acta Medica Kinki University 36(2), 81-86, 2011-12
• … [Abstract] Background : We performed simultaneous hepatectomy and laparoscopic splenectomy in a patient with hepatocellular carcinoma accompaniedby a reduced platelet count caused by hypersplenism. … Hematological analysis included the white blood cell count (WBC), platelet count (Plt), serum alanine transaminase (ALT), total serum bilirubin (T-Bil), prothrombin time (PT)％, and serum albumin (Alb). …
• NAID 120003753066

• 敗血症性ショックと播種性血管内凝固症候群を合併した気腫性膀胱炎の1例

• 仁科 雅良/須賀 弘泰/出口 善純/横山 利光/佐藤 孝幸/西久保 俊士/増田 崇光/中川 隆雄
• 東京女子医科大学雑誌 81(3), 185-188, 2011-06-25
• 気腫性膀胱炎は特徴的な画像所見を呈するまれな疾患である。今回我々は敗血症性ショックと播種性血管内凝固症候群を合併した気腫性膀胱炎の1例を経験したので報告する。症例は74歳の男性。他院から敗血症性ショックのため搬送された。尿閉・血尿・気尿がみられた。腹部単純レントゲン撮影では骨盤部に透亮像があり、腹部造影CT撮影では膀胱内および膀胱壁に気体像がみられた。尿培養ではKlebsiella が検出された。 …
• NAID 110008585261

Related Links

• Platelet count | definition of platelet count by Medical dictionary

Platelet Count Definition A platelet count is a diagnostic test that determines the number of platelets in the patient's blood. Platelets, which are also called thrombocytes, are small disk-shaped blood cells produced in the bone marrow ...

• Platelet count: MedlinePlus Medical Encyclopedia

LOW PLATELET COUNT A low platelet count is below 150,000. If you do not have enough platelets, you may bleed too much. If your platelet count is below 50,000, your risk of bleeding is much higher. Even every day ...

Related Pictures

---

★リンクテーブル★

リンク元	「血小板」「出血性疾患」「platelet number」
拡張検索	「blood platelet count」
関連記事	「count」

「血小板」

　　[★]

英

platelet (Z), blood platelet (Z), PLT

同

栓球 thrombocyte

関

血小板血栓。血小板数 platelet count PLC

• GOO. 1468(血小板凝集 platelet aggregation)
• 半減期:1週間(異常値の出るメカニズム第2版)。4日 (SP.505)。
• 寿命：10日
• 体積：5-10 fl
• 直径：2-5μm。
• 無核。

基準値

• 15万 - 40万 /μl (2007前期解剖学授業プリント, SP.505)
• 15万 - 35万 /μl (2007前期生理学授業プリント, PT.233)

新生児

• 10-28万/mm3 (SPE.74)

パニック値

出典不明

• ≦3万 /μl、≧100万 /ul

産生組織

• 骨髄の巨核球

トロンボポエチンにより巨核球の細胞質がちぎれて血流に放出される (SP.505)

貯蔵組織

• 約1/3が脾臓に存在

組織学

• α顆粒 α-granule

P-セレクチンを膜上に持つ

フィブリノーゲン、フィブロネクチン、第V因子、第VIII因子、platelet factor 4、PDGF、TGF-α (BPT.89)

• 濃染顆粒　dense body

ADP、ATP、Ca2+、ヒスタミン、セロトニン、エピネフリン (BPT.89)

機能 (SAN.236-237)

1.一次止血

• (1) 内皮が剥離した部位にvWFが結合
• (2) 血小板のGpIb/GpIXを介してvWFに結合
• (3) GpIIb/IpIIIa複合体を膜状に発現。血小板が変形し顆粒を放出(ADP, TXA₂,セロトニン)

TXA₂,セロトニンは血管収縮作用

ADP, TXA₂,セロトニンは血小板凝集

• 血小板のGpIIb/GpIIIa複合体がフィブリノゲンと結合し編み目を形成

2.血液凝固の促進

• 血小板表面のリン脂質がIX因子やX因子を結合し活性化する

3.毛細血管機能の維持

• 毛細血管内皮細胞に融合し血管内皮を補強している　→　血小板減少により点状出血を来すことになる。

膜タンパク

ファミリー	慣用名	CD分類	リガンド	機能	欠損症
インテグリン	GpIIb	CD41	フィブリノゲン	凝集	Glanzmann血小板無力症(GT)
	GpIIIa	CD61
LRG	GpIb	CD42bc	vWF	粘着	ベルナール・スリエ症候群(BSS)
	GpIX	CD42a
	GpV	CD42d

血小板減少による症状

• 5-10万　：症状なし-やや止血しにくい程度
• 2-3万　 ：下肢に点状出血 (→皮下出血)
• 1万以下 ：粘膜出血→臓器出血の危険あり

検査

• 抗凝固剤としてEDTAを用いた場合、EDTA依存性偽血小板減少をきたすことがある。

臨床関連

数の異常

• 増加：血小板増多症：真性多血症
• 減少：血小板減少症：肝硬変、多発性骨髄腫、巨赤芽球小生貧血、急性骨髄性白血病、播種性血管内凝固、溶血性尿毒症症候群、ITP、TTP
• 不変：→　グランツマン血小板無力症、血友病　　see also. 機能の異常

• 肝硬変(肝線維化のマーカーとして使われる。肝線維化が進むと血小板減少。肝線維化マーカー)　←　トロンボポエチンが肝臓で産生されることと関係していると考えて良い？

機能の異常

• 灰色血小板症候群

• ストレージプール病の一つ。α顆粒の欠如

「出血性疾患」

　　[★]

英

hemorrhagic disease

出血性疾患 (first aid step1 2006 p.301)

Disorder	platelet count	bleeding time	PT　　.	PTT　　.
qualitative platelet defects	－	↑	－	－
thrombocytopenia	↓	↑	－	－
hemophilia A or hemophilia B	－	－	－	↑
von Willebrand's disease	－	↑	－	↑
DIC	↓	↑	↑	↑

「platelet number」

　　[★]

• 血小板数

関

blood platelet count、platelet count、PLT

「blood platelet count」

　　[★]

• 血小板数

関

platelet count、platelet number、PLT

「count」

　　[★]

• n.

• 数、数値

• v.

• 数える、カウントする

関

number、numeral